{"id":"alxn1210","safety":{"commonSideEffects":[{"rate":"null","effect":"Anemia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ALXN1210 is a recombinant form of the human C5 protein, which inhibits the complement system by binding to C5 and preventing its cleavage into C5a and C5b.","oneSentence":"Complement inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:53:39.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Paroxysmal Nocturnal Hemoglobinuria (PNH)"}]},"trialDetails":[{"nctId":"NCT06830798","phase":"PHASE3","title":"Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-02-24","conditions":"Delayed Graft Function, DGF, Kidney Transplant","enrollment":450},{"nctId":"NCT04543591","phase":"PHASE3","title":"Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-10","conditions":"Thrombotic Microangiopathy","enrollment":148},{"nctId":"NCT06291376","phase":"PHASE3","title":"Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-03-29","conditions":"Immunoglobulin A Nephropathy, IgAN","enrollment":510},{"nctId":"NCT05744921","phase":"PHASE3","title":"A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-03-07","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":202},{"nctId":"NCT05746559","phase":"PHASE3","title":"ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2023-04-06","conditions":"Chronic Kidney Disease, CKD, Cardiac Disease","enrollment":736},{"nctId":"NCT07024563","phase":"PHASE3","title":"Study of Ravulizumab in Pediatric Participants With Primary IgAN","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-06-14","conditions":"IgAN, IgAVN, Immunoglobulin A Nephropathy","enrollment":24},{"nctId":"NCT07010302","phase":"PHASE4","title":"Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-05","conditions":"NMOSD","enrollment":540},{"nctId":"NCT06909253","phase":"","title":"Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-15","conditions":"Myasthenia Gravis, Generalized","enrollment":50},{"nctId":"NCT07221838","phase":"PHASE4","title":"A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab","status":"NOT_YET_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2026-02-27","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":75},{"nctId":"NCT05133531","phase":"PHASE3","title":"A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-01","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":190},{"nctId":"NCT05644561","phase":"PHASE3","title":"Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2023-06-24","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":12},{"nctId":"NCT07413250","phase":"","title":"Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2026-01-14","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH","enrollment":50},{"nctId":"NCT07413679","phase":"","title":"Long-term Safety of Danicopan: IPIG Registry-based Cohort Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-08-18","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH","enrollment":50},{"nctId":"NCT07411963","phase":"","title":"Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-11-26","conditions":"Myasthenia Gravis","enrollment":30},{"nctId":"NCT06312644","phase":"","title":"Study of Ultomiris® (Ravulizumab) Safety in Pregnancy","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-12-16","conditions":"Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":75},{"nctId":"NCT07399730","phase":"","title":"Ravulizumab Outcomes in Polish Patients With aHUS","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-04-01","conditions":"Atypical Hemolytic Uremic Syndrome","enrollment":80},{"nctId":"NCT06967480","phase":"","title":"Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-07-31","conditions":"Generalized Myasthenia Gravis, Anti-AChR Antibody Positive","enrollment":40},{"nctId":"NCT07308574","phase":"PHASE4","title":"Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-12-19","conditions":"aHUS, Atypical Hemolytic Uremic Syndrome","enrollment":20},{"nctId":"NCT04564339","phase":"PHASE2","title":"Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-01-19","conditions":"Lupus Nephritis, Immunoglobulin A Nephropathy","enrollment":123},{"nctId":"NCT06578949","phase":"PHASE3","title":"Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-10-10","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH","enrollment":18},{"nctId":"NCT01374360","phase":"","title":"Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2004-10-29","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":6061},{"nctId":"NCT07337395","phase":"","title":"Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-01","conditions":"Myasthenia Gravis Generalised","enrollment":24},{"nctId":"NCT04557735","phase":"PHASE3","title":"Study of Ravulizumab in Pediatric Participants With HSCT-TMA","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-07","conditions":"Thrombotic Microangiopathy","enrollment":41},{"nctId":"NCT06449001","phase":"PHASE3","title":"Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-08-11","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis","enrollment":6},{"nctId":"NCT06633536","phase":"","title":"Real-life Treatment Outcomes of Ravulizumab in PNH","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-02-06","conditions":"Paroxysmal Nocturnal Haemoglobinuria","enrollment":64},{"nctId":"NCT05346354","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-06-23","conditions":"Neuromyelitis Optica Spectrum Disorder","enrollment":12},{"nctId":"NCT06333652","phase":"PHASE2","title":"Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-03-01","conditions":"Preeclampsia","enrollment":14},{"nctId":"NCT04201262","phase":"PHASE3","title":"An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-12-09","conditions":"Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder","enrollment":58},{"nctId":"NCT05972967","phase":"PHASE2","title":"Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab","status":"COMPLETED","sponsor":"Omeros Corporation","startDate":"2023-03-27","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":12},{"nctId":"NCT06411626","phase":"","title":"Home Reported Outcomes in PNH","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-06-11","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":128},{"nctId":"NCT06398158","phase":"","title":"Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-07-10","conditions":"Neuromyelitis Optica","enrollment":35},{"nctId":"NCT04999020","phase":"PHASE2, PHASE3","title":"Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-11-19","conditions":"Dermatomyositis","enrollment":38},{"nctId":"NCT06903130","phase":"","title":"Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"NOT_YET_RECRUITING","sponsor":"National and Kapodistrian University of Athens","startDate":"2025-09-01","conditions":"NMOSD","enrollment":40},{"nctId":"NCT05274633","phase":"","title":"Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-06-17","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":120},{"nctId":"NCT04469465","phase":"PHASE3","title":"Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-16","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":86},{"nctId":"NCT04702568","phase":"PHASE2","title":"A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"TERMINATED","sponsor":"BioCryst Pharmaceuticals","startDate":"2020-12-18","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH","enrollment":19},{"nctId":"NCT05131204","phase":"PHASE3","title":"Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-10-06","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":3},{"nctId":"NCT03056040","phase":"PHASE3","title":"ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-05-17","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":202},{"nctId":"NCT05116774","phase":"PHASE2","title":"BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy","status":"TERMINATED","sponsor":"BioCryst Pharmaceuticals","startDate":"2021-12-06","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":12},{"nctId":"NCT04558918","phase":"PHASE3","title":"Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-25","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":97},{"nctId":"NCT04743804","phase":"PHASE3","title":"Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-06-29","conditions":"Thrombotic Microangiopathy","enrollment":16},{"nctId":"NCT03748823","phase":"PHASE3","title":"Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-02-19","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":139},{"nctId":"NCT04320602","phase":"PHASE4","title":"Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-04-14","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":18},{"nctId":"NCT03920293","phase":"PHASE3","title":"Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-03-12","conditions":"Generalized Myasthenia Gravis","enrollment":175},{"nctId":"NCT02946463","phase":"PHASE3","title":"ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2016-12-12","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":272},{"nctId":"NCT03131219","phase":"PHASE3","title":"Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-08-31","conditions":"Atypical Hemolytic Uremic Syndrome (aHUS)","enrollment":34},{"nctId":"NCT02949128","phase":"PHASE3","title":"Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-01-11","conditions":"Atypical Hemolytic Uremic Syndrome (aHUS)","enrollment":58},{"nctId":"NCT05288816","phase":"PHASE1","title":"A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2016-04-18","conditions":"Healthy","enrollment":16},{"nctId":"NCT05396742","phase":"PHASE1","title":"Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-08-09","conditions":"Healthy","enrollment":49},{"nctId":"NCT05288660","phase":"PHASE1","title":"A Study of a Single Dose of ALXN1210 in Healthy Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2014-08-27","conditions":"Healthy","enrollment":14},{"nctId":"NCT05288673","phase":"PHASE1","title":"A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2015-07-28","conditions":"Healthy","enrollment":16},{"nctId":"NCT05842486","phase":"","title":"Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-01-18","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":92},{"nctId":"NCT05288829","phase":"PHASE1","title":"A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2016-08-19","conditions":"Healthy","enrollment":42},{"nctId":"NCT03406507","phase":"PHASE3","title":"A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-02-22","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":13},{"nctId":"NCT04248465","phase":"PHASE3","title":"An Efficacy and Safety Study of Ravulizumab in ALS Participants","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-03-30","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":382},{"nctId":"NCT04570397","phase":"PHASE3","title":"Ravulizumab and COVID-19","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2020-12-18","conditions":"Covid19, Thrombotic Microangiopathies, Acute Kidney Injury","enrollment":32},{"nctId":"NCT02605993","phase":"PHASE2","title":"Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2016-01-04","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH","enrollment":26},{"nctId":"NCT04369469","phase":"PHASE3","title":"Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-05-10","conditions":"COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome","enrollment":202},{"nctId":"NCT02598583","phase":"PHASE1, PHASE2","title":"Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2015-11-12","conditions":"PNH","enrollment":13},{"nctId":"NCT04390464","phase":"PHASE4","title":"mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2020-05-08","conditions":"COVID19","enrollment":1167}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ARTHRITIS BACTERIAL"},{"count":1,"reaction":"DYSPNOEA EXERTIONAL"},{"count":1,"reaction":"FRACTURE"},{"count":1,"reaction":"GRANULOMA SKIN"},{"count":1,"reaction":"VARICELLA ZOSTER VIRUS INFECTION"}],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ultomiris","Ravulizumab"],"phase":"phase_1","status":"active","brandName":"ALXN1210","genericName":"ALXN1210","companyName":"Alexion Pharmaceuticals, Inc.","companyId":"alexion-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALXN1210 is a complement C5 inhibitor, classified as an antibody inhibitor. It is being studied in clinical trials for various conditions, including COVID-19 severe pneumonia, acute lung injury, and acute respiratory distress syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}